Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry

Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S, Hassel JC, Hauschild A, Herbst R, Jiang R, Kaatz M, Kahler K, Krepler C, Kreuter A, Leiter-Stoppke U, Loquai C, Meier F, Pfohler C, Rudolph A, Schadendorf D, Schiavone M, Schley G, Terheyden P, Ugurel S, Ulrich J, Utikal JS, Weishaupt C, Welzel J, Weichenthal M (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 18-18

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Mohr, P., Scherrer, E., Alar, V., Assaf, C., Beissert, S., Berking, C.,... Weichenthal, M. (2022). Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 18-18). HOBOKEN: WILEY.

MLA:

Mohr, P., et al. "Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2022. 18-18.

BibTeX: Download